Company profile
The Greater Cannabis Company, Inc.
OTC: GCAN · Healthcare · Medical - Pharmaceuticals
#1129 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
14DFH 7DQ 26GM 10SS 22
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$331.6k
Employees
1
as of 2026-08-27
Market cap
$330.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$12.6k$12.6k2021
Net income-$331.6k-$331.6k2025
Operating income-$183.0k-$183.0k2025
Total assets$815$8152025
Liabilities$742.5k$742.5k2025
Equity-$741.6k-$741.6k2025
Revenue trend
FY2017 – FY2021 · USD
FY17
FY18
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is The Greater Cannabis Company, Inc.’s revenue?
The Greater Cannabis Company, Inc. booked $12.6k in FY2021 revenue, contracting 74% year over year — slower than 87% of Healthcare companies we track, at a -2625.6% net margin.
Peers · Healthcare
Wuhan General Group (China), Inc.——Cryomass Technologies Inc.——Relmada Therapeutics, Inc.38DEvolutionary Genomics, Inc.——First Colombia Gold Corp.——Baseline Productions, Inc.——Neighbors
Baltimore (Independent City) →Key facts
CEOPorfirio Sánchez-Talavera
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersBaltimore, MD
ExchangeOTC: GCAN
Employees1
IPO date2018-09-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.